Aarsland, D., Cummings, J. L., Yenner, G., & Miller, B. (1996). Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. American Journal of Psychiatry, 153(2), 243–7.CrossRefGoogle Scholar

Assal, F., Alarcon, M., Solomon, E. C., et al. (2004). Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Archives of Neurology, 61(8), 1249–53.CrossRefGoogle Scholar

Bacanu, S. A., Devlin, B., Chowdari, K. V., et al. (2002). Linkage analysis of Alzheimer disease with psychosis. Neurology, 59, 118–120.CrossRefGoogle Scholar

Bacanu, S. A., Devlin, B., Chowdari, K. V., et al. (2005). Heritability of psychosis in Alzheimer disease. American Journal of Geriatric Psychiatry, 13, 624–27.CrossRefGoogle Scholar

Ballard, C., Massey, H., Lamb, H., & Morris, C. (1997a). Apolipoprotein E: Non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 63, 273.Google Scholar

Ballard, C. G., O'Brien, J. T., Coope, B., & Wilcock, G. (1997b). Psychotic symptoms in dementia and the rate of cognitive decline. Journal of the American Geriatrics Society, 45(8), 1031–2.Google Scholar

Bassiony, M. M., Rosenblatt, A., Baker, A., et al. (2002). The relationship between delusions and depression in Alzheimer's disease. International Journal of Geriatric Psychiatry, 17, 549–56.CrossRefGoogle Scholar

Bhana, N. & Spencer, C. M. (2000). Risperidone: A review of its use in the management of the behavioural and psychological symptoms of dementia. Drugs and Aging, 16(6), 451–71.CrossRefGoogle Scholar

Borroni, B., Agosti, C., Archetti, S., et al. (2004). Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease. Neuroscience Letters, 370(2–3), 127–9.CrossRefGoogle Scholar

Corder, E. H., Saunders, A. M., Strittmatter, W. J. S. D. E., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921–3.CrossRefGoogle Scholar

Craig, D., Hart, D. J., Carson, R., McIlroy, S. P., & Passmore, A. P. (2004). Psychotic symptoms in Alzheimer's disease are not influenced by polymorphic variation at the dopamine receptor DRD3 gene. Neuroscience Letters, 368(1), 33–6.CrossRefGoogle Scholar

Deyn, P. P., Carrasco, M. M., Deberdt, W., et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19(2), 115–26.CrossRefGoogle Scholar

Deutsch, L. H., Bylsma, F. W., Rovner, B. W., Steele, C., & Folstein, M. F. (1991). Psychosis and physical aggression in probable Alzheimer's disease. American Journal of Psychiatry, 148, 1159–63.CrossRefGoogle Scholar

Devanand, D. P., Miller, L., Richards, M., et al. (1992). The Columbia University Scale for Psychopathology in Alzheimer's disease. Archives of Neurology, 49, 371–6.CrossRefGoogle Scholar

Devanand, D. P., Jacobs, D. M., Tang, M. X., et al. (1997). The course of psychopathologic features in mild to moderate Alzheimer disease. Archives of General Psychiatry, 54, 257–63.CrossRefGoogle Scholar

Drevets, W. C. & Rubin, E. H. (1989). Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biological Psychiatry, 25, 39–48.CrossRefGoogle Scholar

Farber, N. B., Rubin, E. H., Newhouse, P. A., et al. (2000). Increased neocortical neurofibrillary tangle density in subjects with Alzheimer's disease. Archives of General Psychiatry, 57, 1165–73.CrossRefGoogle Scholar

FDA Public Health Advisory (2005). Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Posted 4/11/2005. US Food and Drug Administration, accessed 4/15/2005.

Forstl, H., Burns, A., Levy, R., & Cairns, N. (1994). Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. British Journal of Psychiatry, 165, 53–9.CrossRefGoogle Scholar

Glatt, S. J., Faraone, S. V., & Tsuang, M. T. (2003). Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: Meta-analysis of case-control and family-based studies. American Journal of Psychiatry, 160(3), 469–76.CrossRefGoogle Scholar

Go, R. C., Perry, R. T., Weiner, H., et al. (2004). Neuregulin-1 polymorphism in LOAD with psychosis in the NIMH AD sibling families. Neurobiology of Aging, 25(S2), 488.CrossRefGoogle Scholar

Gurevich, E. V., Bordelon, Y., Shapiro, R. M., et al. (1997). Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia: A postmortem study. Archives of General Psychiatry, 54, 225–32.CrossRefGoogle Scholar

Harwood, D. G., Barker, W. W., Ownby, R. L., St. George-Hyslop, P. H., & Duara, R. (1999). Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease. American Journal of Geriatric Psychiatry, 7, 119–23.CrossRefGoogle Scholar

Herrmann, N., Mamdani, M., & Lanctot, K. L. (2004). Atypical antipsychotics and risk of cerebrovascular accidents. American Journal of Psychiatry, 161(6), 1113–15.CrossRefGoogle Scholar

Holmes, C., Arranz, M. J., Powell, J. F., Collier, D., & Lovestone, S. (1998). 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Human Molecular Genetics, 7(9), 1507–9.CrossRefGoogle Scholar

Holmes, C., Smith, H., Ganderton, R., et al. (2001). Psychosis and aggression in Alzheimer's disease: The effect of dopamine receptor gene variation. Journal of Neurology, Neurosurgery, and Psychiatry, 71(6), 777–9.CrossRefGoogle Scholar

Jeste, D. V. & Finkel, S. I. (2000). Psychosis of Alzheimer's disease and related dementias. American Journal of Geriatric Psychiatry, 8(1), 29–34.CrossRefGoogle Scholar

Jeste, D. V., Wragg, R. E., Salmon, D. P., Harris, M. J., & Thal, L. J. (1992). Cognitive deficits of patients with Alzheimer's disease with and without delusions. American Journal of Psychiatry, 149(2), 184–9.CrossRefGoogle Scholar

Jeste, D. V., Deyn, P., Carson, W., et al. (2003). Aripiprazole in dementia of the Alzheimer's type. Journal of the American Geriatrics Society, 51(4), S226.Google Scholar

Kaufer, D. I., Cummings, J. L., Christine, D., et al. (1998). Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale. Journal of the American Geriatrics Society, 46(2), 210–15.CrossRefGoogle Scholar

Kehoe, P., Wavrant-De Vrieze, F., Crook, R., et al. (1999). A full genome scan for late onset Alzheimer's disease. Human Molecular Genetics, 8(2), 237–45.CrossRefGoogle Scholar

Keshavan, M. S., Stanley, J. A., & Pettegrew, J. W. (2000). Magnetic resonance spectroscopy in schozphrenia: Methological issues and findings: Part II. Biological Psychiatry, 48(5), 369–80.CrossRefGoogle Scholar

Kukull, W. A., Higdon, R., Bowen, J. D., et al. (2002). Dementia and Alzheimer disease incidence: A prospective cohort study. Archives of Neurology, 59(11), 1737–46.CrossRefGoogle Scholar

Lai, M. K. P., Lai, O. F., Keene, J., et al. (2001). Psychosis of Alzheimer's disease is associated with elevated muscarinic M-2 binding in the cortex. Neurology, 57(5), 805–11.CrossRefGoogle Scholar

Levy, M. L., Cummings, J., Fairbanks, L. A., et al. (1996). Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. American Journal of Psychiatry, 153, 1438–43.CrossRefGoogle Scholar

Lohmueller, K. E., Pearce, C. L., Pike, M., Lander, E. S., & Hirschhorn, J. N. (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nature Genetics, 33(2), 177–82.CrossRefGoogle Scholar

Lopez, O. L., Kamboh, M. I., Becker, J. T., Kaufer, D. I., & DeKosky, S. T. (1997). The apolipoprotein E ε4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology, 49, 794–7.CrossRefGoogle Scholar

Lopez, O. L., Wisniewski, S. R., Becker, J. T., Boller, F., & DeKosky, S. T. (1999). Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Archives of Neurology, 56(10), 1266–72.CrossRefGoogle Scholar

Lyketsos, C. G., Steinberg, M., Tschanz, J. T., et al. (2000). Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry, 157(5), 708–14.CrossRefGoogle Scholar

Lyketsos, C. G., Sheppard, J. M., Steinberg, M., et al. (2001). Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: The Cache County study. International Journal of Geriatric Psychiatry, 16(11), 1043–53.CrossRefGoogle Scholar

Lyketsos, C. G., Lopez, O., Jones, B., et al. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. Journal of the American Medical Association, 288(12), 1475–83.CrossRefGoogle Scholar

Magni, E., Binetti, G., Bianchetti, A., & Trabucchi, M. (1996). Risk of mortality and institutionalization in demented patients with delusions. Journal of Geriatric Psychiatry and Neurology, 9, 123–6.CrossRefGoogle Scholar

Mukaetova-Ladinska, E. B., Harrington, C. R., Xuereb, J., Roth, M., & Wischik, C. M. (1995). Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In Treating Alzheimer's and Other Dementias, ed. Bergener, M. & Finkel, S. I.. New York: Springer, pp. 57–80.

Nacmias, B., Tedde, A., Forleo, P., et al. (2001). Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biological Psychiatry, 50(6), 472–5.CrossRefGoogle Scholar

Paulsen, J. S., Ready, R. E., Stout, J. C., et al. (2000a). Neurobehaviors and psychotic symptoms in Alzheimer's disease. Journal of the International Neuropsychological Society, 7, 815–20.Google Scholar

Paulsen, J. S., Salmon, D. P., Thal, L., et al. (2000b). Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology, 54(10), 1965–71.Google Scholar

Perez-Madrinan, G., Cook, S. E., Saxton, J. A., et al. (2004). Alzheimer disease with psychosis: Excess cognitive impairment is restricted to the misidentification subtype. American Journal of Geriatric Psychiatry, 12(5), 449–56.Google Scholar

Pollock, B. G., Mulsant, B. H., Rosen, J., et al. (2002). A randomized, double-blind, placebo-controlled comparison of citalopram and perphenazine for the acute treatment of psychosis and behavioral disturbances associated with dementia. American Journal of Psychiatry, 159(3), 460–65.CrossRefGoogle Scholar

Ramachandran, G., Marder, K., Tang, M., et al. (1996). A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology, 47, 256–9.CrossRefGoogle Scholar

Richards, S. S. & Sweet, R. A. (1999). Treating psychosis in Alzheimer's disease. Alzheimer's Disease Management Today, 2(3), 3–9.Google Scholar

Rocchi, A., Micheli, D., Ceravolo, R., et al. (2003). Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): Association studies with psychosis in Alzheimer disease. Genetic Testing, 7(4), 309–14.CrossRefGoogle Scholar

Rockwell, E., Jackson, E., Vilke, G., & Jeste, D. V. (1994). A study of delusions in a large cohort of Alzheimer's disease patients. American Journal of Geriatric Psychiatry, 2, 157–64.CrossRefGoogle Scholar

Schneider, L. S. & Dagerman, K. S. (2004). Psychosis of Alzheimer's disease: Clinical characteristics and history. Journal of Psychiatric Research, 38(1), 105–11.CrossRefGoogle Scholar

Schneider, L. S., Dagerman, K. & Insel, P. S. (2006). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo- controlled trials. American Journal of Geriatric Psychiatry, 14(3), 191–210.CrossRefGoogle Scholar

Shifman, S., Bronstein, M. S. M., Pisante-Shalom, A., et al. (2002). A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics, 71(6), 1296–302.CrossRefGoogle Scholar

Smith, D. A. & Beier, M. T. (2004). Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism. Journal of the American Medical Directory Association, 5(2), 129–32.CrossRefGoogle Scholar

Starkstein, S. E., Vazquez, S., Petracca, G., et al. (1994). A SPECT study of delusions in Alzheimer's disease. Neurology, 44, 2055–59.CrossRefGoogle Scholar

Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., et al. (2002). Neuregulin 1 and susceptibility to schizophrenia. American Journal of Human Genetics, 71(4), 877–92.CrossRefGoogle Scholar

Steinberg, M., Tschanz, J. T., Corcoran, C., et al. (2004). The persistence of neuropsychiatric symptoms in dementia: The Cache County Study. International Journal of Geriatric Psychiatry, 19(1), 19–26.CrossRefGoogle Scholar

Stern, Y., Mayeux, R., Sano, M., Hauser, W. A., & Bush, T. (1987). Predictors of disease course in patients with probable Alzheimer's disease. Neurology, 37, 1649–53.CrossRefGoogle Scholar

Street, J. S., Clark, W. S., Gannon, K. S., et al. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry, 57(10), 968–76.CrossRefGoogle Scholar

Streim, J. E., McQuade, R., Stock, E., et al. (2004). Aripiprazole for the treatment of institutionalized patients with psychosis of Alzheimer's dementia. Journal of the American Geriatrics Society, 52(4), S15.Google Scholar

Sukonick, D. L., Pollock, B. G., Sweet, R. A., et al. (2001). The 5-HTTPR polymorphism and aggressive behavior in Alzheimer's disease. Archives of Neurology, 58, 1425–8.CrossRefGoogle Scholar

Sultzer, D. L., Mahler, M. E., Mandelkern, M. A., et al. (1995). The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 476–84.Google Scholar

Sweet, R. A., Nimgaonkar, V. L., Kamboh, M. I., et al. (1998). Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease. Archives of Neurology, 55, 1335–40.CrossRefGoogle Scholar

Sweet, R. A., Hamilton, R. L., Lopez, O. L., et al. (2000). Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. International Psychogeriatrics, 12(4), 547–58.CrossRefGoogle Scholar

Sweet, R. A., Hamilton, R. L., Healy, M. T., et al. (2001a). Alterations of striatal dopamine receptor binding in Alzheimer's disease are associated with lewy body pathology and with antemortem psychosis. Archives of Neurology, 58, 466–72.Google Scholar

Sweet, R. A., Pollock, B. G., Sukonick, D. L., et al. (2001b). The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer's disease. International Psychogeriatrics, 13(4), 401–9.Google Scholar

Sweet, R. A., Kamboh, M. I., Wisniewski, S. R., et al. (2002a). APOE and ACT genotypes do not predict time to psychosis in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology, 15(1), 24–30.Google Scholar

Sweet, R. A., Nimgaonkar, V. L., Devlin, B., Lopez, O. L., & DeKosky, S. T. (2002b). Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology, 58, 907–11.Google Scholar

Sweet, R. A., Panchalingam, K., Pettegrew, J. W., et al. (2002c). Psychosis in Alzheimer disease: Postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiology of Aging, 23(4), 547–53.Google Scholar

Sweet, R. A., Devlin, B., Pollock, B.G., et al. (2004). Catechol-O-methyltransferase haplotype is associated with psychosis in Alzheimer disease. Proceedings of the American Association for Geriatric Psychiatry 17th Annual Meeting.

Tariot, P. N., Mack, J. L., Patterson, M. B., et al. (1995). The behavior rating scale for dementia of the Consortium to Establish a Registry for Alzheimer's Disease. American Journal of Psychiatry, 152(9), 1349–57.CrossRefGoogle Scholar

Tariot, P. N., Farlow, M. R., Grossberg, G. T., et al. (2004a). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. Journal of the American Medical Association, 291(3), 317–24.Google Scholar

Tariot, P. N., Profenno, L. A., & Ismail, M. S. (2004b). Efficacy of atypical antipsychotics in elderly patients with dementia. Journal of Clinical Psychiatry, 65(Suppl. 11), 11–15.Google Scholar

Tariot, P. N., Schneider, L., Katz, J. R., et al. (2006). Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. American Journal of Geriatric Psychiatry, 14(9), 767–76.CrossRefGoogle Scholar

Tractenberg, R. E., Weiner, M. F., Patterson, M. B., Teri, L., & Thal, L. J. (2003). Comorbidity of psychopathological domains in community-dwelling persons with Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology, 16(2), 94–9.CrossRefGoogle Scholar

Tunstall, N., Fraser, L., Lovestone, S., et al. (2000). Familial influence on variation in age of onset and behavioural phenotype in Alzheimer's disease. British Journal of Psychiatry, 176, 156–9.CrossRefGoogle Scholar

Wilkosz, P. A., Miyahara, S., Lopez, O. L., DeKosky, S. T., & Sweet, R. A. (2004). Psychotic symptoms identify subtypes of AD: A prospective validation study. Neurobiology of Aging, 25(S2), 495.CrossRefGoogle Scholar

Wooltorton, E. (2002). Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 167(11), 1269–70.Google Scholar

Wooltorton, E. (2004). Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. Canadian Medical Association Journal, 170(9), 1395.CrossRefGoogle Scholar

Wragg, R. E. & Jeste, D. V. (1989). Overview of depression and psychosis in Alzheimer's disease. American Journal of Psychiatry, 146, 577–87.CrossRefGoogle Scholar

Wynn, Z. J. & Cummings, J. L. (2004). Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dementic and Geriatric Cognitive Disorders, 17, (1–2), 100–108.CrossRefGoogle Scholar

Yang, J. Z., Si, T. M., Ruan, Y., et al. (2003). Association study of neuregulin 1 gene with schizophrenia. Molecular Psychiatry, 8(7), 706–9.CrossRefGoogle Scholar

Zubenko, G. S., Moossy, J., Martinez, A. J., et al. (1991). Neuropathologic and neurochemical correlates of psychosis in primary dementia. Archives of Neurology, 48, 619–24.CrossRefGoogle Scholar